NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences
COSTA MESA, CA -- (Marketwired) -- 09/07/16 -- NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing, and commercializing cannabinoid therapeutics, announces that it will present at two investor conferences in September, 2016. Dr. Brian Murphy, CEO, will present at The Rodman & Renshaw 18th Annual Global Investment Conference in New York City, and the Aegis Capital Growth Conference in Las Vegas, where the management team will also conduct one-on-one meetings with investors.
Rodman & Renshaw 18th Annual Global Investment Conference
Date: September 11-13, 2016
Location: Lotte New York Palace Hotel
Presentation: Tuesday, September 13, 2016 at 9:10 a.m. Eastern Time
Conference Website: http://www.hcwainwright.com/conference
Aegis Capital Corp. 2016 Growth Conference
Date: September 20-22, 2016
Location: The Encore at Wynn, Las Vegas, NV
Presentation: Thursday, September 22, 2016 at 1:00 p.m. Pacific Time
Conference Website: http://bit.ly/2bJlmzA
Conference participation is by invitation only and registration is mandatory. For more information on the conferences or to schedule a one-on-one meeting with management, please contact the respective conference representatives. Additionally, feel free to contact Adam Holdsworth, NEMUS' investor relations representative, at adamh@pcgadvisory.com or 646-862-4607.
ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS' strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development. For more information, visit http://www.nemusbioscience.com.
CONTACTS:
Adam Holdsworth, Investor Relations
Email: adamh@pcgadvisory.com
Phone: 646-862-4607
Janet Vasquez, Public Relations
Email: jvasquez@jvprny.com
Phone: 212-645-5498
FORWARD LOOKING STATEMENTS
Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.
CONTACTS:
Adam Holdsworth
Investor Relations
Email: adamh@pcgadvisory.com
Phone: 646-862-4607
Janet Vasquez
Public Relations
Email: jvasquez@jvprny.com
Phone: 212-645-5498
Source: NEMUS Bioscience, Inc.
Released September 7, 2016